Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells Sir -We read with interest the paper by Perry et al. (1995) reporting pharmacological modulation of transforming growth factor P1 (TGF-fli) expression in MCF-7 cells by mechanisms that appear to be independent of the conventional oestrogen receptor (ER) and that may involve either transcriptional or post-transcnrptional events.
Our group have previously reported induction of this potent epithelial growth inhibitor by tamoxifen in fetal fibroblasts in vitro and proposed a negative paracrine hypothesis (Colletta et al.. 1990) . Consistent wAith this concept of a direct action of tamoxifen upon fibroblasts. we subsequently demonstrated stromal induction of TGF-13, in both ER-positive and ER-negative breast cancers follow%ing primary tamoxifen therapy (Butta et al.. 1992) . Up-regulation was seen prodominantly between and around stromal fibroblasts. with little increased immunoreactivity in the vicinity of epithelial cells. In this respect, these results were at variance with previous in vitro studies showing induction of TGF-,B by tamoxifen in MCF-7 cells (Knabbe et al.. 1987 ). The present study concurs with the latter observations and supports the existence of both functional autocrine and paracrine inhibitory loops involving TGF-f3, (Benson and Colletta. 1995). However. previous work on induction of TGF-fl, in breast carcinoma cell lines revealed that this response to anti-oestrogens was confined to ER-positive (MCF-7) cells. and growth inhibition of ER-negative cells was only observed when these were co-cultured in the presence of MCF-7 cells, which alone could respond to tamoxifen and produce TGF-fl. which acted in a negative paracrine manner upon ER-negative cells (Knabbe et al.. 1987) . These results were consistent with tamoxifen acting via the ER with TGF-fl, being a proximate growth modulator.
We have recently confirmed induction of TGF-fl, in the breast tumour fibroblasts in vitro in the absence of any detectable ER protein (Benson et al.. 1995) . The modulation of TGF-J, expression in both ER-positive and ER-negative breast cancer cells observed in the present study may reflect a common ER-independent mechanism of action that is operative in both epithelial cells and fibroblasts. However, it should be noted that the concentrations of tamoxifen employed in this study were relatively high. In our own in vitro experiments. maximal induction was observed at tamoxifen concentrations of between 500 and 1000 nm. and similar concentrations induced TGF-13, in MCF-7 cells. A biphasic pattern of growth inhibition of breast cancer cells by anti-oestrogens has been observed. with an E2 reversible effect at concentrations of 10-1000 nm. and an E2 irreversible inhibition at concentrations of 1-10 pm (Sutherland et al.. 1986 ). Although specific non-ER-mediated mechanisms cannot be excluded. it is possible that growth inhibition at higher concentrations represents a direct cytotoxic action of tamoxifen upon cells. Indeed. Bronzert et al. (1985) reported the maximal non-cytotoxic growthinhibitory doses of anti-oestrogens to be <1 pm for MCF-7 cells.
These considerations raise the issue of whether the concentrations of tamoxifen used in the present study exert non-specific cytotoxic effects rather than formally activating pathways leading to enhanced TGF-f production. Programmed cell death could result from such non-specific action. and indeed may be a final common pathway for many cytotoxic agents. Any apparent increases in cytosolic TGF-f31 protein could be a consequence of defective secretion with intracellular retention secondarv to cytotoxic effects of tamoxifen. It is noteworthy that the induction of TGF-,B was relatively modest. with 2-3 times probably being the minimal fold induction with physiological consequence. Much greater magnitudes of induction have been witnessed in vitro (Colletta et al.. 1990 : Benson et al.. 1995 We agree that current evidence suggests that tamoxifen may act via a post-transcriptional mechanism at lower concentrations and a transcriptional mechanism at higher concentrations.
Whether such mechanistic differences are important in determining the therapeutic effectiveness in vivo remain to be determined.
